The Claim
In obese mice, inhibition of 15-PGDH increases prostaglandin E2 (PGE2) signaling in muscle stem cells, which enhances proliferation and rescues myogenic differentiation impaired by semaglutide via activation of EP2/EP4 receptors and CREB-dependent pathways.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, blocking the enzyme 15-PGDH raises prostaglandin E2 levels in muscle stem cells, leading to increased cell division and restoration of muscle cell development that was suppressed by semaglutide, through activation of EP2/EP4 receptors and CREB signaling pathways.
See the scientific wording
In obese mice, 15-PGDH inhibition increases prostaglandin E2 (PGE2) signaling in muscle stem cells, enhancing their proliferation and rescuing myogenic differentiation impaired by semaglutide, through EP2/EP4 receptor and CREB-dependent pathways.
When the enzyme that breaks down PGE2 is blocked, PGE2 builds up in muscle tissue and binds to specific receptors on muscle stem cells. This triggers a chain reaction inside the cells that turns on genes needed for the cells to multiply and mature into new muscle fibers, reversing the block caused by reduced nutrient intake.
What the research says
1 studyIn obese mice taking a weight-loss drug that weakens muscle repair, blocking a specific enzyme (15-PGDH) helped their muscles heal better and get stronger — without stopping the weight loss. It’s like removing a brake that was slowing down muscle recovery.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.